Delving into the Latest Updates on PalloV-CC(Cancer Insight) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Colonic Cancer

Inactive Indication-

Originator Organization

LumaBridge LLCStartup

Active Organization

LumaBridge LLCStartup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This study is a phase Ib prospective, open label study evaluating the effect of vaccination on the immune microenvironment of cancers with results compared to banked tissue from historical controls. Prospectively vaccinated patients will also serve as their own controls by comparing the immune microenvironment of the tumor in pre-treatment biopsies to post-treatment surgical specimens. This is also a dose-escalation study with consecutive enrollment and advancement of cohorts in an overlapping fashion.

Start Date20 Jul 2019

Sponsor / Collaborator

LumaBridge LLCStartup

100 Clinical Results associated with PalloV-CC(Cancer Insight)

Login to view more data

100 Translational Medicine associated with PalloV-CC(Cancer Insight)

Login to view more data

100 Patents (Medical) associated with PalloV-CC(Cancer Insight)

Login to view more data

100 Deals associated with PalloV-CC(Cancer Insight)

Login to view more data